PE20120023A1 - Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva - Google Patents

Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva

Info

Publication number
PE20120023A1
PE20120023A1 PE2011001533A PE2011001533A PE20120023A1 PE 20120023 A1 PE20120023 A1 PE 20120023A1 PE 2011001533 A PE2011001533 A PE 2011001533A PE 2011001533 A PE2011001533 A PE 2011001533A PE 20120023 A1 PE20120023 A1 PE 20120023A1
Authority
PE
Peru
Prior art keywords
aerosols
concentration
active
pharmaceutical formulation
total formulation
Prior art date
Application number
PE2011001533A
Other languages
English (en)
Inventor
Erhard Berkel
Hubert Hoelz
Friedrich Schmidt
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38266105&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120023(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of PE20120023A1 publication Critical patent/PE20120023A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/124—Aerosols; Foams characterised by the propellant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) MONOHIDRATO DE BROMURO DE IPATROPIO DISUELTO EN COMBINACION CON SULFATO DE SALBUTAMOL COMO PRINCIPIO ACTIVO; B) UN PROPELENTE HIDROCARBURO FLUORADO TAL COMO 1,1,1,2-TETRAFLUOROETANO O 1,1,1,2,3,3,3-HEPTAFLUOROPROPANO; C) UN CO-SOLVENTE TAL COMO ETANOL EN UNA CONCENTRACION DE 0.0001 A 50% (m/m) DE LA FORMULACION TOTAL; D) UN TENSIOACTIVO TAL COMO MONOLAURATO DE POLIOXIETILENO-20-SORBITANO EN UNA CONCENTRACION DE 0.001 A 5% (m/m); E) UN ESTABILIZANTE TAL COMO ACIDO CITRICO, ACIDO ASCORBICO, CLORURO DE BENZALCONIO, ENTRE OTROS, EN UNA CONCENTRACION DE 0.0001 A 0.02% (m/m) DE LA FORMULACION TOTAL. DICHA COMPOSICION PARA AEROSOLES ES UTIL EN EL TRATAMIENTO DE ASMA, ENFERMEDAD PULMONAR OBSTRUCTIVA CRONICA
PE2011001533A 2006-02-09 2007-02-07 Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva PE20120023A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102006006207 2006-02-09
DE102006053374A DE102006053374A1 (de) 2006-02-09 2006-11-10 Pharmazeutische Formulierung für Aerosole mit zwei oder mehr Wirkstoffen und mindestens einer oberflächenaktiven Substanz

Publications (1)

Publication Number Publication Date
PE20120023A1 true PE20120023A1 (es) 2012-02-13

Family

ID=38266105

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2011001533A PE20120023A1 (es) 2006-02-09 2007-02-07 Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
PE2007000132A PE20070951A1 (es) 2006-02-09 2007-02-07 Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2007000132A PE20070951A1 (es) 2006-02-09 2007-02-07 Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva

Country Status (19)

Country Link
US (1) US20070183982A1 (es)
EP (1) EP1988874A2 (es)
JP (1) JP2009526012A (es)
KR (1) KR20080098656A (es)
CN (1) CN102861339A (es)
AR (1) AR059350A1 (es)
AU (1) AU2007213819B2 (es)
BR (1) BRPI0707594A2 (es)
CA (1) CA2641883A1 (es)
DE (1) DE102006053374A1 (es)
EA (1) EA014776B1 (es)
EC (1) ECSP088653A (es)
IL (1) IL193274A0 (es)
NO (1) NO20083375L (es)
NZ (1) NZ571016A (es)
PE (2) PE20120023A1 (es)
TW (1) TW200800294A (es)
UY (1) UY30139A1 (es)
WO (1) WO2007090822A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2391563T5 (es) * 2004-07-02 2022-10-26 Boehringer Ingelheim Int Formulaciones en suspensión de aerosol con TG 227 ea como agente propulsor
DE102006017320A1 (de) * 2006-04-11 2007-10-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel
GB0712454D0 (en) 2007-06-27 2007-08-08 Generics Uk Ltd Pharmaceutical compositions
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
EP2662472B1 (de) 2009-03-31 2019-02-27 Boehringer Ingelheim International Gmbh Verfahren zur Beschichtung einer Oberfläche eines Bauteils
EP3508239B1 (de) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
SG181050A1 (en) 2009-11-25 2012-07-30 Boehringer Ingelheim Int Nebulizer
WO2011160932A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nebulizer
WO2012087094A1 (es) * 2010-12-21 2012-06-28 Techsphere S.A. De C.V. Composición farmacéutica inhalable para el tratamiento del asma por administración vía aérea mediante un succionador de emulación de aerosol
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
GB201306984D0 (en) * 2013-04-17 2013-05-29 Mexichem Amanco Holding Sa Composition
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
PL2835146T3 (pl) 2013-08-09 2021-04-06 Boehringer Ingelheim International Gmbh Nebulizator
RU2536253C1 (ru) * 2013-10-09 2014-12-20 Шолекс Девелопмент Гмбх Комбинированный аэрозольный препарат для лечения болезней органов дыхания
WO2015169759A1 (en) 2014-05-07 2015-11-12 Boehringer Ingelheim International Gmbh Nebulizer and container
BR112016023983B1 (pt) 2014-05-07 2022-10-18 Boehringer Ingelheim International Gmbh Contentor para um nebulizador, nebulizador para um fluido e método para conectar um contentor a um dispositivo indicador
US10722666B2 (en) 2014-05-07 2020-07-28 Boehringer Ingelheim International Gmbh Nebulizer with axially movable and lockable container and indicator
EP2985019B1 (en) 2014-08-16 2021-10-20 Church & Dwight Co., Inc. Nasal composition having anti-viral properties
EP3280393A1 (en) * 2015-04-10 2018-02-14 3M Innovative Properties Company Formulation and aerosol canisters, inhalers, and the like containing the formulation
GB2573297A (en) * 2018-04-30 2019-11-06 Mexichem Fluor Sa De Cv Pharmaceutical composition
CN110876723A (zh) * 2018-09-06 2020-03-13 天津金耀集团有限公司 一种含有表面活性剂的异丙托溴铵喷雾剂

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1230472A (es) * 1967-07-10 1971-05-05
DE3767615D1 (de) * 1986-03-10 1991-02-28 Kurt Burghart Pharmazeutikum sowie verfahren zu seiner herstellung.
WO1992022286A1 (en) * 1991-06-12 1992-12-23 Minnesota Mining And Manufacturing Company Albuterol sulfate suspension aerosol formulations
US5503869A (en) * 1994-10-21 1996-04-02 Glaxo Wellcome Inc. Process for forming medicament carrier for dry powder inhalator
EP0806940B1 (en) * 1994-12-22 2003-04-09 AstraZeneca AB Aerosol drug formulations
US6392962B1 (en) * 1995-05-18 2002-05-21 Rmp, Inc. Method of sleep time measurement
GB9626960D0 (en) * 1996-12-27 1997-02-12 Glaxo Group Ltd Valve for aerosol container
GB2332372B (en) * 1997-12-08 2002-08-14 Minnesota Mining & Mfg Pharmaceutical aerosol compositions
RU2218152C2 (ru) * 1998-06-18 2003-12-10 Берингер Ингельхайм Фармасьютикэлс, Инк. Фармацевтическая композиция для аэрозолей с двумя или большим количеством действующих веществ
US6423298B2 (en) * 1998-06-18 2002-07-23 Boehringer Ingelheim Pharmaceuticals, Inc. Pharmaceutical formulations for aerosols with two or more active substances
US6352152B1 (en) * 1998-12-18 2002-03-05 Smithkline Beecham Corporation Method and package for storing a pressurized container containing a drug
WO2003045357A1 (en) * 2001-11-27 2003-06-05 Transform Pharmaceuticals, Inc. Oral pharmaceutical formulations comprising paclitaxel, derivatives and methods of administration thereof
SE0200312D0 (sv) * 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
GB0207899D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and cielesonide aerosol formulations
EP2319584A1 (en) * 2002-08-29 2011-05-11 Cipla Ltd. Pharmaceutical products and compositions comprising salmeterol, ciclesonide and tiotropium
CA2519523C (en) * 2003-03-20 2012-03-13 Boehringer Ingelheim Pharmaceuticals, Inc. Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants
US20050191246A1 (en) * 2003-12-13 2005-09-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powders comprising low molecular dextran and methods of producing those powders
US20050239778A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim International Gmbh Novel medicament combinations for the treatment of respiratory diseases
US7611709B2 (en) * 2004-05-10 2009-11-03 Boehringer Ingelheim Pharma Gmbh And Co. Kg 1,4 O-linked saccharose derivatives for stabilization of antibodies or antibody derivatives
US7723306B2 (en) * 2004-05-10 2010-05-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Spray-dried powder comprising at least one 1,4 O-linked saccharose-derivative and methods for their preparation
US7727962B2 (en) * 2004-05-10 2010-06-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Powder comprising new compositions of oligosaccharides and methods for their preparation
ES2391563T5 (es) * 2004-07-02 2022-10-26 Boehringer Ingelheim Int Formulaciones en suspensión de aerosol con TG 227 ea como agente propulsor

Also Published As

Publication number Publication date
WO2007090822A3 (de) 2007-11-08
CA2641883A1 (en) 2007-08-16
DE102006053374A1 (de) 2007-08-16
JP2009526012A (ja) 2009-07-16
BRPI0707594A2 (pt) 2011-05-10
EA014776B1 (ru) 2011-02-28
IL193274A0 (en) 2009-08-03
KR20080098656A (ko) 2008-11-11
NO20083375L (no) 2008-10-30
UY30139A1 (es) 2007-09-28
ECSP088653A (es) 2008-10-31
WO2007090822A2 (de) 2007-08-16
EP1988874A2 (de) 2008-11-12
CN102861339A (zh) 2013-01-09
TW200800294A (en) 2008-01-01
AR059350A1 (es) 2008-03-26
NZ571016A (en) 2012-01-12
PE20070951A1 (es) 2007-09-24
EA200801767A1 (ru) 2009-02-27
AU2007213819A1 (en) 2007-08-16
AU2007213819B2 (en) 2012-11-15
US20070183982A1 (en) 2007-08-09

Similar Documents

Publication Publication Date Title
PE20120023A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
Sanguinetti N-acetylcysteine in COPD: why, how, and when?
PE20010627A1 (es) Composiciones que tienen estabilidad mejorada
PE20121467A1 (es) Formulacion de aerosol para la enfermedad pulmonar obstructiva cronica
PE20121396A1 (es) Composicion farmaceutica que comprende bromuro de glicopirronio y formoterol
BRPI0913326B8 (pt) formulação aquosa para aplicação tópica à pele contendo uma baixa concentração de peróxido de benzoíla e método para preparação da dita formulação
CR9832A (es) Compuestos de pirimidina amida como inhibidores de pgds
PE20080204A1 (es) Formulaciones farmaceuticas que comprenden un anticolinergico y un beta agonista
PE20091691A1 (es) Formulacion para inhalacion que comprende aclidinio
CZ20004750A3 (en) pharmaceutical preparation
RS52940B (en) PHARMACEUTICAL FORMULATIONS OF SOLUTION FOR MEASURED DOSES OF PRESSURE INHALATORS
AR038641A1 (es) Formulacion superfina de formoterol
CL2008003301A1 (es) Compuestos derivados de 3,4-dihidropirazina-2-carboxamida, inhibidores de la elastasa de neutrofilos humanos; composiciones farmacéuticas; procesos de preparación de compuestos y composición farmacéutica; y uso en el tratamiento de síndrome de dificultad respiratoria de los adultos, fibrosis quística, cáncer, entre otras.
AR067184A1 (es) Uso de 6-(3-cloro-2-fluorbencil)-1-[(2s)-1-hidroxi-3-metilbutan-2-il]-7-metoxi-4-oxo-1,4-dihidroquinolina-3-carboxilico. composicion farmaceutica
MX2009003002A (es) Formulaciones de tensioactivos pulmonares y metodos para promover la aclaracion del moco.
PE20070353A1 (es) Formulaciones de disoluciones de hfc que contienen hidrocloruro de salbutamol o citrato de salbutamol
PE20081759A1 (es) Composicion farmaceutica que comprende un agonista del adrenoceptor b2
AR055591A1 (es) Una composicion topica protectora de la piel y su uso
NO20064661L (no) Oyenlosning som innbefatter natriumkarboksymetylcellulose og hydroksypropylmetylcellulose
JP2013535472A5 (es)
PE20141048A1 (es) Combinacion que comprende umeclidinio y un corticosteroide
AR082049A1 (es) Formulaciones liquidas de rupatadina fumarato
JOP20200314A1 (ar) تركيبات صيدلانية مستقرة لأجهزة إستنشاق جرعات مضغوطة معايرة الجرعة
PE20030970A1 (es) Formulacion de aerosol para inhalacion que contiene una sal de tiotropio
JP2015504860A5 (es)

Legal Events

Date Code Title Description
FD Application declared void or lapsed